Form 4: Ovid Therapeutics Director Barbara Gayle Duncan Granted 45,000 Stock Options

Ovid Therapeutics Inc. director Barbara Gayle Duncan was granted 45,000 stock options with an exercise price of $0.57, vesting fully on February 20, 2026.

Summary

• Barbara Gayle Duncan, a Director of Ovid Therapeutics Inc. (OVID), was granted 45,000 stock options.
• The stock options have an exercise price of $0.57 per share.
• The grant date for these options was February 20, 2025.
• The options will vest in full on February 20, 2026, contingent upon Ms. Duncan's continuous service to the company.
• The expiration date for these options is February 19, 2035.
• Following this transaction, Ms. Duncan beneficially owns 45,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (stock option grant) which is generally a neutral to slightly positive event as it aligns director interests with shareholders. It does not contain significant positive or negative news beyond this standard compensation.

Positives

• The grant of stock options aligns the interests of Director Barbara Gayle Duncan with those of shareholders, incentivizing long-term performance.
• The options serve as a retention mechanism, contingent on continuous service through the vesting date.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shares, although this is a standard component of equity compensation.

Risks

• The vesting of the options is subject to the reporting person's continuous service through the vesting date, meaning the options could be forfeited if service ceases before February 20, 2026.

Future Outlook

The document indicates a future vesting event for the granted stock options on February 20, 2026, contingent on the director's continuous service.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to align executive and board member incentives with long-term shareholder value creation and to attract and retain talent.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across publicly traded companies, including those in the biotechnology sector like Ovid Therapeutics Inc.
• The specific terms, such as the number of options (45,000) and the exercise price ($0.57), are typically determined by the company's compensation committee based on factors like the director's role, company performance, and market benchmarks for similar positions.
• The vesting schedule (full vesting after one year) is a common approach to ensure continued commitment and service from board members.

Related Party Transactions

• The stock option grant to Director Barbara Gayle Duncan constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making. However, future exercise could result in minor dilution.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this specific filing.

Next Steps

• The stock options are scheduled to vest in full on February 20, 2026, provided the reporting person maintains continuous service.
• The options will remain exercisable until their expiration date of February 19, 2035.

Key Dates

Recommendation

Keywords

Ovid Therapeutics, OVID, SEC Form 4, Stock Option Grant, Director Compensation, Equity Compensation, Insider Transaction, Beneficial Ownership, Barbara Gayle Duncan